{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:27:26Z","timestamp":1791840446332,"version":"4.3.4"},"reference-count":34,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>PF-06649751 is a novel, oral, non-catechol-based, D1\/D5 dopamine receptor partial agonist under investigation for the treatment of motor symptoms associated with Parkinson\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A 15-week, phase\u2009II, double-blind, placebo-controlled clinical trial was conducted to assess the efficacy and safety of flexible-dose PF-06649751 in subjects with early stage Parkinson\u2019s disease (ClinicalTrials.gov identifier: NCT02847650).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Enrollment was terminated early for reasons unrelated to the trial. Overall, 57 subjects received study medication (PF-06649751\u2009=\u200929; placebo\u2009=\u200928) and 47 completed the study (PF-06649751\u2009=\u200925; placebo\u2009=\u200922). Despite early termination, the study met its primary endpoint with the PF-06649751 group showing statistically significant improvement from baseline in the Movement Disorder Society-Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS) Part\u2009III score at week\u200915 compared with placebo. Mean (SE) change in MDS-UPDRS Part\u2009III score was \u22129.0 (1.54) for PF-06649751 and \u22124.3 (1.65) for placebo. This corresponds to an improvement versus placebo of 4.8 for the PF-06649751 group (two-sided p\u2009=\u20090.0407; 90% CI\u2009=\u20091.0, 8.6). Statistically significant improvement in MDS-UPDRS-III score was also observed at all assessment time points prior to week 15. The safety profile of PF-06649751 was similar to that observed in prior studies, with the majority of adverse events (AEs) reported as mild or moderate. The most common AEs in the PF-06649751 group were nausea, headache, dry mouth, somnolence, and tremor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Once-daily dosing of oral PF-06649751 resulted in significant improvement of motor symptoms and was generally well tolerated in subjects with early stage Parkinson\u2019s disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1756286420911296","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T07:09:14Z","timestamp":1583478554000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":54,"title":["PF-06649751 efficacy and safety in early Parkinson\u2019s disease: a randomized, placebo-controlled trial"],"prefix":"10.1177","volume":"13","author":[{"given":"Robert","family":"Riesenberg","sequence":"first","affiliation":[{"name":"Atlanta Center for Medical Research, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Werth","sequence":"additional","affiliation":[{"name":"Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Duvvuri","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Cambridge, MA, USA"},{"name":"Current address: Cerevel Therapeutics, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gray","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Cambridge, MA, USA"},{"name":"Current address: Cerevel Therapeutics, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"key":"bibr1-1756286420911296","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00109"},{"key":"bibr2-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.151179"},{"key":"bibr3-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-018-0587-4"},{"key":"bibr4-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2017.07.033"},{"key":"bibr5-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13"},{"key":"bibr6-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.136"},{"key":"bibr7-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27372"},{"key":"bibr8-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2014.09.009"},{"key":"bibr9-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3654"},{"key":"bibr10-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2015.07.002"},{"key":"bibr11-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-018-1900-6"},{"key":"bibr12-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0566-3"},{"key":"bibr13-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1007\/s11515-015-1360-4"},{"key":"bibr14-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1016\/0306-3623(88)90005-5"},{"key":"bibr15-1756286420911296","first-page":"1582","volume":"2","author":"Mailman R","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"key":"bibr16-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199906)45:6<736::AID-ANA7>3.0.CO;2-F"},{"key":"bibr17-1756286420911296","first-page":"339","volume":"21","author":"Blanchet PJ","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"bibr18-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.2.249"},{"key":"bibr19-1756286420911296","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Mirapex US prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020667s034lbl.pdf (accessed November 30 2018)."},{"key":"bibr20-1756286420911296","unstructured":"GlaxoSmithKline. Requip US prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020658s034lbl.pdf (accessed 30 November 2018). prescribing information"},{"key":"bibr21-1756286420911296","unstructured":"UCB Inc. Neupro US prescribing information, https:\/\/www.neupro.com\/neupro-prescribing-information.pdf?v=1489766618 (accessed 30 November 2018)."},{"key":"bibr22-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12733"},{"key":"bibr23-1756286420911296","volume":"2","author":"Stowe RL","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr24-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-018-0114-z"},{"key":"bibr25-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"bibr26-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"bibr27-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1002\/mds.24023"},{"key":"bibr28-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31817efbac"},{"key":"bibr29-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1207\/s15327752jpa6703_13"},{"key":"bibr30-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/14.6.540"},{"key":"bibr31-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1007\/PL00007730"},{"key":"bibr32-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"bibr33-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.295"},{"key":"bibr34-1756286420911296","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25122"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756286420911296","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1756286420911296","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756286420911296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T16:34:23Z","timestamp":1740933263000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756286420911296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":34,"alternative-id":["10.1177\/1756286420911296"],"URL":"https:\/\/doi.org\/10.1177\/1756286420911296","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"1756286420911296"}}